The bone marrow ORR in this interim analysis was 21%.

Interim (3 month) Analysis

This will be further explored in trials of tosedostat in combination with hypomethylating agents.

In vitro blast proliferation assays [2].

• Synergy between tosedostat and both cytarabine and demethylating agents seen in AML
• No significant cardiovascular disease
• No anti-cancer therapy within 2 weeks of trial entry except hydroxyurea.

• Adequate hepatic and renal function, PS ≤ 2, and LVEF ≥ 50%

METHODS

• Based on these results, the phase 2 comparing two doses of single agent tosedostat in

• A phase 1/2 study of tosedostat in elderly and/or relapsing patients with AML or

• Tosedostat targets intracellular members of the M1/17 family of aminopeptidases. Causing

 gaanaghthin anti-leukemic effects and acceptable
tolerability. The ORR for patients with AML was 27% [3].

• The true response rates may be higher than the interim evaluation due to the long time to

• Nine of 23 (39%) patients with prior hypomethylating agent therapy had a response supporting

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.

• Daily and tosedostat is reasonably well tolerated and has anti-leukemic activity in elderly patients with relapsed and refractory AML.

• The true response rates may be higher than the interim evaluation due to the long time to response observed with tosedostat.

• The final analysis will be available when all patients have completed the 24 week evaluation.

• This will be further explained in trials of tosedostat in combination with hypomethylating agents.